| Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among … RM Emanuel, AC Dueck, HL Geyer, JJ Kiladjian, S Slot, S Zweegman, ... Journal of clinical oncology 30 (33), 4098-4103, 2012 | 531 | 2012 |
| Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma … K Hartmann, L Escribano, C Grattan, K Brockow, MC Carter, ... Journal of Allergy and Clinical Immunology 137 (1), 35-45, 2016 | 440 | 2016 |
| The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients R Scherber, AC Dueck, P Johansson, T Barbui, G Barosi, AM Vannucchi, ... Blood, The Journal of the American Society of Hematology 118 (2), 401-408, 2011 | 420 | 2011 |
| High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H CE Dearden, E Matutes, B Cazin, GE Tjønnfjord, A Parreira, B Nomdedeu, ... Blood, The Journal of the American Society of Hematology 98 (6), 1721-1726, 2001 | 393 | 2001 |
| Guideline for investigation and management of adults and children presenting with a thrombocytosis. CN Harrison, D Bareford, N Butt, P Campbell, E Conneally, M Drummond, ... British journal of haematology 149 (3), 2010 | 362 | 2010 |
| The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis RA Mesa, S Schwager, D Radia, A Cheville, K Hussein, J Niblack, ... Leukemia research 33 (9), 1199-1203, 2009 | 282 | 2009 |
| Systemic mastocytosis C Akin, DD Metcalfe Annu. Rev. Med. 55 (1), 419-432, 2004 | 275 | 2004 |
| The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia B Cheung, D Radia, P Pantelidis, G Yadegarfar, C Harrison British journal of haematology 132 (2), 244-245, 2006 | 203 | 2006 |
| Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal P Valent, C Akin, K Hartmann, I Alvarez-Twose, K Brockow, O Hermine, ... Hemasphere 5 (11), e646, 2021 | 196 | 2021 |
| Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis P Valent, L Escribano, S Broesby‐Olsen, K Hartmann, C Grattan, ... Allergy 69 (10), 1267-1274, 2014 | 190 | 2014 |
| Guideline for the investigation and management of eosinophilia N Butt, J Lambert, S Ali, P Beer, N Cross, A Duncombe, J Ewing, ... British journal of haematology 176 (4), 2017 | 174 | 2017 |
| Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal P Valent, K Sotlar, WR Sperr, L Escribano, S Yavuz, A Reiter, TI George, ... Annals of oncology 25 (9), 1691-1700, 2014 | 144 | 2014 |
| Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients HL Geyer, RM Scherber, AC Dueck, JJ Kiladjian, Z Xiao, S Slot, ... Blood, The Journal of the American Society of Hematology 123 (24), 3803-3810, 2014 | 122 | 2014 |
| Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial J Gotlib, A Reiter, DH Radia, MW Deininger, TI George, J Panse, ... Nature medicine 27 (12), 2192-2199, 2021 | 107 | 2021 |
| Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients K Gowin, P Thapaliya, J Samuelson, C Harrison, D Radia, B Andreasson, ... haematologica 97 (10), 1570, 2012 | 106 | 2012 |
| Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial DJ DeAngelo, DH Radia, TI George, WA Robinson, AT Quiery, ... Nature medicine 27 (12), 2183-2191, 2021 | 105 | 2021 |
| Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib BS Wilkins, D Radia, C Woodley, S El Farhi, C Keohane, CN Harrison Haematologica 98 (12), 1872, 2013 | 91 | 2013 |
| Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease H Geyer, R Scherber, H Kosiorek, AC Dueck, JJ Kiladjian, Z Xiao, S Slot, ... Journal of Clinical Oncology 34 (2), 151-159, 2016 | 84 | 2016 |
| The management and outcome of 18 pregnancies in women with polycythemia vera S Robinson, S Bewley, BJ Hunt, DH Radia, CN Harrison haematologica 90 (11), 1477-1483, 2005 | 84 | 2005 |
| Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series Y Beauverd, D Radia, C Cargo, S Knapper, M Drummond, A Pillai, ... Haematologica 101 (5), e182, 2016 | 67 | 2016 |
